Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis

INTRODUCTION: Treatment with disease-modifying therapies (DMT) in patients with clinically isolated syndrome (CIS) represents standard care in multiple sclerosis (MS) patients nowadays. Since a proportion of patients may show no evidence of disease activity (NEDA) after some time of treatment, the q...

Descripción completa

Detalles Bibliográficos
Autores principales: Monschein, Tobias, Salhofer-Polanyi, Sabine, Altmann, Patrick, Zrzavy, Tobias, Dal-Bianco, Assunta, Bsteh, Gabriel, Rommer, Paulus, Berger, Thomas, Leutmezer, Fritz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990829/
https://www.ncbi.nlm.nih.gov/pubmed/32929591
http://dx.doi.org/10.1007/s00415-020-10074-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990829/
https://www.ncbi.nlm.nih.gov/pubmed/32929591
http://dx.doi.org/10.1007/s00415-020-10074-4

Ejemplares similares